GlassScriptPhysician profile
Jamie Bice
NPI 1679152151
$1,203.05
in general payments reported to CMS, 2019-2025
21 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.37 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $300.56 | 2025 | |
| Argenx US, INC. | $118.24 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $90.45 | 2025 | |
| Ucb, INC. | $81.03 | 2025 | Rystiggo, Briviact |
| Otsuka America Pharmaceutical, INC. | $71.39 | 2025 | Rexulti |
| Neurelis, INC. | $71.20 | 2025 | Valtoco |
| Eisai INC. | $68.18 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.80 | 2025 | Hyqvia |
| Lundbeck LLC | $48.28 | 2025 | Vyepti |
| Amgen INC. | $41.51 | 2025 | |
| Acadia Pharmaceuticals INC | $33.59 | 2025 | Nuplazid |
| Janssen Biotech, INC. | $26.92 | 2025 | |
| Tg Therapeutics, INC. | $25.44 | 2025 | |
| Medtronic, INC. | $24.69 | 2025 | Inceptiv |
| Emd Serono, INC. | $23.21 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.05 | 2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $21.68 | 2025 | |
| Axsome Therapeutics, INC. | $20.59 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $18.15 | 2025 | Wainua |
| Biogen, INC. | $17.84 | 2025 | Leqembi |
| Abbvie INC. | $15.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Bice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.